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Correction to: VULCAN integrates ChIP-seq
with patient-derived co-expression
networks to identify GRHL2 as a key co-
regulator of ERa at enhancers in breast
cancer
Andrew N. Holding1,2*† , Federico M. Giorgi1,3†, Amanda Donnelly1, Amy E. Cullen1, Sankari Nagarajan1,
Luke A. Selth4 and Florian Markowetz1
Correction to: Genome Biol (2019) 20:91
https://doi.org/10.1186/s13059-019-1698-z
Following publication of the original article [1], the
authors reported that Figs. 4 and 5 had mistakenly been
transposed. Please find the correct Figs. 4 and 5 below.
The original article [1] has been corrected.
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Fig. 4 Global TF activity after estradiol treatment using different network models. XY scatter showing the TF activity as calculated by VULCAN for
our differential ChIP-seq analysis of ER binding at 45 min (a) and at 90 min (b) after stimulation with 100 nM E2. Comparison of the results
calculated using the METABRIC (y-axis) and TCGA (x-axis) networks shows consistent results know ER interactors including PGR, RARA, GATA3, and
GRHL2. GRHL2 activity is notably enriched against. The regulon of ER is also consistently enriched in both networks. Pearson’s correlation
coefficient (PCC) shown along with the significance
Fig. 5 Inferring TF co-occupancy in public datasets with VULCAN. a VULCAN activity scores for a few TFs derived from the ER-targeted ChIP-seq breast
cancer patient-derived xenograft (PDX) dataset GSE110824. The behavior of ESR1, FOXA1, and GATA3 is correlated, while FOXC1 shows an inversely
correlated pattern (blue line). Interestingly, the sample with the lowest Allred score (V0980 U) has the lowest activity and the other luminal markers.
b VULCAN activity scores for FOXA1 in ChIP-seq experiments targeting the androgen receptor (AR) in LNCaP-1F5 prostate-derived cells (dataset
GSE39880). The bar plots show the relative VULCAN normalized enrichment score calculated on absolute peak intensities after treating cells with
dihydrotestosterone (DHT) and partial AR modulators cyproterone acetate (CPA) and mifepristone (RU486). FOXA1 network binding is higher in the
presence of the strong AR recruiter DHT. This shows an increased FOXA1/AR promoter co-occupancy in DHT-treated cells, in agreement with the
conclusions of the study that originated the dataset. Two replicates for each treatment were produced and are reported in matching colors
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